Mark Voll Joins RenovoRx as Chief Financial Officer

RenovoRx Inc. has welcomed a new member to its senior leadership team, hiring Mark Voll as chief financial officer (CFO), effective Feb. 1.

Voll has more than three decades of financial leadership experience as well as a strong track record for guiding high-growth public companies through periods of commercial buildout and strategic development. He has served as CFO for multiple publicly traded technology companies where he successfully led corporate initiatives that scaled early growth to full commercial development.

Voll will assume a forward-facing role in stockholder communications and leverage his experience in budgeting, strategic planning, and finance. His expertise in managing operations will be instrumental as RenovoRx continues the commercialization of its RenovoCath drug-delivery device and simultaneously advances its Phase III TIGeR-PaC clinical trial.

“We are thrilled to welcome Mark to the RenovoRx leadership team during this important chapter of our company’s history,” RenovoRx CEO Shaun Bagai said. “During 2025, we moved from being solely a clinical stage company to a commercial one as well. Mark is therefore joining us at a perfect time as we look to capitalize on our evolving model. His financial and operational leadership experience in both public markets and high-growth organizations will play a critical role as RenovoRx continues its drive towards sustained commercial execution.”

Throughout his career, Voll has guided companies through initial public offerings and subsequent exits, including Techwell Inc. (IPO in 2006, acquired by Intersil in 2010), Montage Technology (IPO in 2013, acquired by PDSTI in 2014), and Aquantia Corporation (IPO in 2017, acquired by Marvell Technology in 2019).

Voll leads a finance team that includes Ronald B. Kocak (who was principal accounting officer until Voll’s appointment) for a transitional period as well as Lilly Huang, who previously worked with Voll and recently joined RenovoRx as executive director of Finance.

“I’ve worked with many emerging growth companies in my career, and I believe that RenovoRx right now is very well positioned at the intersection of innovation and patient impact, with a differentiated therapy platform and a clear strategic vision for transforming the lives of cancer patients,” Voll stated. “I have spent my career helping high-growth companies scale, and I am excited to bring that experience to RenovoRx. The team has built a strong foundation and has positive momentum, and I look forward to collaborating with leadership and the entire organization to further accelerate RenovoRx’s success.”

Based on its U.S. Food and Dru Administration (FDA) clearance, RenovoCath is intended to isolate blood flow and fluid delivery, including diagnostic and/or therapeutic agents, to select sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.

RenovoRx Inc. develops targeted oncology therapies and commercializes RenovoCath. Its patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to target therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy.

RenovoRx is in the early stages of actively commercializing the TAMP therapy platform and FDA-cleared RenovoCath as a stand-alone device. In December 2024, RenovoRx announced the receipt of its first commercial purchase orders for RenovoCath devices, and for the first nine months of 2025, approximately $900,000 of revenues were generated from RenovoCath sales. Several customers have already initiated repeat orders in parallel to RenovoRx expanding the number of medical institutions initiating new RenovoCath orders. To meet and satisfy the anticipated demand, RenovoRx will continue to actively explore further revenue-generating activity, either on its own or in tandem with a medical device commercial partner.

RenovoRx is also evaluating a novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered through RenovoCath, known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of the FDA) under a U.S. investigational new drug application. The combination product candidate (IAG), which is enabled by the RenovoCath device, is currently under investigation and has not been approved for commercial sale.